Prime Medicine, Inc.
NASDAQ:PRMEBiotechnology
-$0.04 today
- Market cap
- $694.94M
- Beta
- 2.31
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$1.12
Volume 4.62M
Average 2.47M
PRME Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Prime Medicine, Inc.NASDAQ: PRME
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue dips below year-ago levels
Q1 FY2026 revenue of $856K fell 41.1% year over year, behind the +4.9% change in trailing-twelve-month revenue. Sequentially, it rose 2.1% from the prior quarter.
Context
- Revenue increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 8 analysts of $10.7M (+130.9%) for the fiscal year ending Dec 2026, a step up from the +55.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $856K+2.1% QoQ
- Last fiscal yearDec 2025
- $4.63M+55.3% YoY
- LTMMar 2026
- $4.03M+4.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -41.1% | +101.9% | +143.0 pp |
| 1 year | +55.3% | +130.9% | +75.6 pp |
| 3-year CAGR | — | +74.5% | — |
| 5-year CAGR | +87.0% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 4.63M USD
- Year-over-year change
- +55.3%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.63M | +55.3% |
| FY2024 | 2024-12-31 | 2.98M | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Revenue vs competitors
How PRME compares with its peers on the latest reported figures
- PRME's LTM Mar 2026 revenue of $4.03M is the 6th highest of the 7 companies compared; the peer median is $31.93M.
- Its year-over-year change of +4.9% is the 5th highest of 6, against a peer median of +13.0%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | $156.04M | +158.9% | +31.9% | |
| LTM Mar 2026 | $66.09M | +45.0% | +9.1% | |
| LTM Mar 2026 | $38.69M | +8.0% | +27.1% | |
| LTM Sep 2026 | $25.17M | -33.1% | +100.4% | |
| LTM Mar 2026 | $11.2M | +13.0% | -7.0% | |
| LTM Mar 2026 | $4.03M | +4.9% | — | |
| LTM Mar 2026 | $0 | — | — | |
SCTXScribe Therapeutics Inc. | — | — | — | — |
| Peer median (excluding PRME) | $31.93M | +13.0% | +27.1% | |
Competitors are the stored peer set for PRME. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 2.98M | 4.63M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 7.32M |
| Gross Profit | 0 | 0 | 0 | 2.98M | (2.69M) |
| Gross Margin | — | — | — | 100.0% | -58.1% |
| Research & Development | 70.55M | 86.73M | 147.91M | 155.29M | 160.64M |
| Selling, General & Admin | 13.92M | 29.82M | 43.39M | 50.16M | 52.35M |
| Operating Expenses | 84.47M | 116.54M | 204.79M | 205.45M | 205.66M |
| Depreciation & Amortization | 568K | 2.22M | 4.65M | 6.13M | 5.38M |
| EBITDA | (165.29M) | (120.55M) | (186.64M) | (189.75M) | (195.76M) |
| EBITDA Margin | — | — | — | -6361.2% | -4226.2% |
| Operating Income | (84.47M) | (116.54M) | (204.79M) | (202.47M) | (208.35M) |
| Operating Margin | — | — | — | -6787.4% | -4498.1% |
| Interest Income | 0 | 0 | 0 | 3.52M | 4.15M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (81.38M) | (6.23M) | 6.38M | 6.59M | 7.21M |
| Income Before Tax | (165.85M) | (122.77M) | (198.41M) | (195.88M) | (201.14M) |
| Pre-Tax Margin | — | — | — | -6566.6% | -4342.4% |
| Income Tax Expense | (486K) | (948K) | (279K) | 0 | 0 |
| Net Income | (165.37M) | (121.82M) | (198.13M) | (195.88M) | (201.14M) |
| Net Margin | — | — | — | -6566.6% | -4342.4% |
| EPS (Basic) | (1.92) | (1.46) | (2.18) | (1.65) | (1.35) |
| EPS (Diluted) | (1.92) | (1.46) | (2.18) | (1.65) | (1.35) |
| Weighted Avg Shares | 95.73M | 97.21M | 90.97M | 118.6M | 148.76M |
| Weighted Avg Shares (Diluted) | 95.73M | 97.21M | 90.97M | 118.6M | 148.76M |
Prime Medicine, Inc.
NASDAQ:PRME
Intrinsic Alpha fair value
Locked
Current Price
$3.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.